Novavax, Inc.NVAX stock score: 55/100
$7.72 · -3.02% · Scored Nov 19, 2026
- Technical
- 27
- Fundamental
- 62
- News
- —
The reading
Novavax (NVAX) scores 55 out of 100, which reads neutral, higher than 61% of Healthcare stocks and 61% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 62, technicals 27.
Among the fundamentals, Price Target at 100 and Earnings Growth (Annual) at 100 score highest, while Earnings Growth (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 15 and contrarian oscillators 72 — a split worth reading before trusting the technical total.
Since Aug 22, 2026 the composite has ranged from 47 to 58, and it is up 3 points over the period.
About Novavax
Novavax (NVAX) is a biotechnology company based in Gaithersburg, Maryland, that develops protein-based vaccines and the Matrix-M adjuvant, an ingredient that strengthens the immune response to a vaccine. Its main product is Nuvaxovid, a protein-based COVID-19 vaccine, which Sanofi now commercializes in most markets under a licensing agreement. Under that arrangement, Novavax earns royalties on Sanofi’s sales, milestone payments and revenue from supplying product during a manufacturing transfer, and Sanofi can use Novavax’s technology in combination vaccines, including a planned COVID-19 and influenza shot. Novavax also licenses Matrix-M to other drug makers, including Pfizer, for use in their vaccines and earns licensing fees and potential royalties. The company has cut costs sharply and shifted toward a partnering model rather than selling vaccines itself.
Novavax’s technology competes with messenger RNA vaccines from Pfizer and BioNTech and from Moderna, as well as with vaccines and adjuvants from GSK, CSL Seqirus and others. Its edge rests on a protein-based vaccine platform with a well-understood safety profile, the Matrix-M adjuvant and a major partner that handles commercialization. Investors who follow NVAX stock tend to watch royalty and milestone income from Sanofi. Progress on Sanofi’s combination vaccine and new Matrix-M licensing deals are closely followed. Vaccine policy and recommendations, operating costs, cash balance and convertible debt are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward NVAX’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
62Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Net income growth from the prior fiscal year to the latest.
Return on Assets (ROA) shows how efficiently a company uses its assets to generate profit.
Holding it back
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.
Share of the float sold short.
34 weighted scorers; 5 had no data today and are left out rather than counted as zero.
Technical · daily
22Pulling it up
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Williams %R (28-period) places the close within the last 28 periods' high-low range.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Performance versus SPY compares the stock's returns to the S&P 500 index.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 36 | 1 |
| Daily | 22 | 3 |
| Weekly | 28 | 2 |
| Monthly | 28 | 2 |
| Quarterly | 30 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 55 |
| Nov 18, 2026 | 56 |
| Nov 17, 2026 | 55 |
| Nov 16, 2026 | 55 |
| Nov 15, 2026 | 56 |
| Nov 14, 2026 | 56 |
| Nov 13, 2026 | 56 |
| Nov 12, 2026 | 58 |
| Nov 11, 2026 | 49 |
| Nov 10, 2026 | 50 |
| Nov 8, 2026 | 53 |
| Nov 7, 2026 | 53 |
| Nov 6, 2026 | 52 |
| Nov 5, 2026 | 49 |
| Nov 4, 2026 | 52 |
| Nov 3, 2026 | 49 |
| Nov 2, 2026 | 48 |
| Nov 1, 2026 | 49 |
| Oct 31, 2026 | 49 |
| Oct 30, 2026 | 49 |
| Oct 29, 2026 | 50 |
| Oct 28, 2026 | 50 |
| Oct 27, 2026 | 49 |
| Oct 26, 2026 | 47 |
| Oct 25, 2026 | 48 |
| Oct 24, 2026 | 48 |
| Oct 23, 2026 | 48 |
| Oct 22, 2026 | 49 |
| Oct 21, 2026 | 52 |
| Oct 20, 2026 | 52 |
| Oct 19, 2026 | 51 |
| Oct 18, 2026 | 52 |
| Oct 17, 2026 | 52 |
| Oct 16, 2026 | 52 |
| Oct 15, 2026 | 55 |
| Oct 14, 2026 | 56 |
| Oct 13, 2026 | 56 |
| Oct 12, 2026 | 57 |
| Oct 11, 2026 | 57 |
| Oct 10, 2026 | 57 |
| Oct 9, 2026 | 56 |
| Oct 8, 2026 | 54 |
| Oct 7, 2026 | 54 |
| Oct 6, 2026 | 55 |
| Oct 5, 2026 | 56 |
| Oct 4, 2026 | 53 |
| Oct 3, 2026 | 53 |
| Oct 2, 2026 | 53 |
| Oct 1, 2026 | 53 |
| Sep 30, 2026 | 55 |
| Sep 29, 2026 | 54 |
| Sep 28, 2026 | 55 |
| Sep 27, 2026 | 55 |
| Sep 26, 2026 | 55 |
| Sep 25, 2026 | 55 |
| Sep 24, 2026 | 55 |
| Sep 23, 2026 | 56 |
| Sep 22, 2026 | 55 |
| Sep 21, 2026 | 55 |
| Sep 20, 2026 | 54 |
| Sep 19, 2026 | 54 |
| Sep 18, 2026 | 54 |
| Sep 17, 2026 | 54 |
| Sep 16, 2026 | 52 |
| Sep 15, 2026 | 51 |
| Sep 14, 2026 | 52 |
| Sep 13, 2026 | 53 |
| Sep 12, 2026 | 52 |
| Sep 11, 2026 | 52 |
| Sep 10, 2026 | 51 |
| Sep 9, 2026 | 53 |
| Sep 8, 2026 | 55 |
| Sep 7, 2026 | 55 |
| Sep 6, 2026 | 55 |
| Sep 5, 2026 | 55 |
| Sep 4, 2026 | 55 |
| Sep 3, 2026 | 55 |
| Sep 2, 2026 | 56 |
| Sep 1, 2026 | 55 |
| Aug 31, 2026 | 54 |
| Aug 30, 2026 | 53 |
| Aug 29, 2026 | 54 |
| Aug 28, 2026 | 53 |
| Aug 27, 2026 | 52 |
| Aug 26, 2026 | 53 |
| Aug 25, 2026 | 54 |
| Aug 24, 2026 | 52 |
| Aug 23, 2026 | 52 |
| Aug 22, 2026 | 52 |
Key facts
- Market cap
- $1.3B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 2.72
- Risk grade (1–10)
- 7
- Next earnings
- Nov 5, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| INVA Innoviva | $1.3B | 63 |
| LBRX LB Pharmaceuticals | $1.3B | 41 |
| OCUL Ocular Therapeutix | $1.3B | 38 |
| GHRS GH Research | $1.3B | 42 |
| MNKD MannKind | $1.3B | 56 |
| MLYS Mineralys Therapeutics | $1.3B | 31 |
Questions
What is NVAX's stock rating today?
NVAX scores 55/100 (Neutral) as of Nov 19, 2026: technical 27, fundamental 62. Scores are recomputed every night.
What does Novavax do?
Novavax (NVAX) is a biotechnology company based in Gaithersburg, Maryland, that develops protein-based vaccines and the Matrix-M adjuvant, an ingredient that strengthens the immune response to a vaccine. Its main product is Nuvaxovid, a protein-based COVID-19 vaccine, which Sanofi now commercializes in most markets under a licensing agreement.
Is NVAX stock a buy?
The score is not a buy or sell recommendation. A 55 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the NVAX score calculated?
96 weighted scorers feed it today: 34 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/nvax/"><img src="https://stocksscores.com/stocks/nvax/badge.svg" alt="NVAX stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/nvax/)